Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching from Dulaglutide to Tirzepatide in Type 2 Diabetes
NCT05564039Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2022
- Primary completion
- Jul 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
Phase 4, randomised, open-label trial of tirzepatide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change From Baseline in HbA1c at Week 40. Started Nov 2022; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05564039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05564039.